APA (7th ed.) Citation

H, A. (2026). Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer. Drug design, development and therapy, 20, 611371. https://doi.org/10.2147/DDDT.S611371

Chicago Style (17th ed.) Citation

H, Abdel-Razeq. "Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer." Drug Design, Development and Therapy 20 (2026): 611371. https://doi.org/10.2147/DDDT.S611371.

MLA (9th ed.) Citation

H, Abdel-Razeq. "Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer." Drug Design, Development and Therapy, vol. 20, 2026, p. 611371, https://doi.org/10.2147/DDDT.S611371.